A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets

NCT02466815 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: JNJ-42756493 Current Clinical Formulation (G-018)
DRUG: JNJ-42756493 Prototype Formulation I (G-025)
DRUG: JNJ-42756493 Prototype Formulation II (G-025)

Sponsor

Janssen Research & Development, LLC